This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and/or to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D.
Deadlines:
Letter of Intent Due Date(s): May 22, 2021
Application Due Date(s): June 22, 2021
RFA-DK-21-005 Expiration Date June 23, 2021
Application budgets are limited to $600,000 direct costs per year. The budget needs to reflect the scientific scope of the proposed project.
The maximum project period is 5 years.
